Ross Weinreb

Stock Analyst at Goldman Sachs

(0.09)
# 3,774
Out of 4,670 analysts
3
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:

Stocks Rated by Ross Weinreb

Relmada Therapeutics
Mar 24, 2022
Maintains: Buy
Price Target: $69$53
Current: $2.80
Upside: +1,792.86%